Abstract
Long-chain EPA/DHA omega-3 fatty acid supplementation can be co-preventative and co-therapeutic. Current research suggests increasing accumulated long chain omega-3s for health benefits and as natural medicine in several major diseases. But many believe plant omega-3 sources are nutritionally and therapeutically equivalent to the EPA/DHA omega-3 in fish oil. Although healthy, precursor ALA bio-conversion to EPA is inefficient and production of DHA is nearly absent, limiting the protective value of ALA supplementation from flax-oil, for example. Along with pollutants certain fish acquire high levels of EPA/DHA as predatory species. However, the origin of EPA/DHA in aquatic ecosystems is algae. Certain microalgae produce high levels of EPA or DHA. Now, organically produced DHA-rich microalgae oil is available. Clinical trials with DHA-rich oil indicate comparable efficacies to fish oil for protection from cardiovascular risk factors by lowering plasma triglycerides and oxidative stress. This review discusses 1) omega-3 fatty acids in nutrition and medicine; 2) omega-3s in physiology and gene regulation; 3) possible protective mechanisms of EPA/DHA in major diseases such as coronary heart disease, atherosclerosis, cancer and type 2 diabetes; 4) EPA and DHA requirements considering fish oil safety; and 5) microalgae EPA and DHA-rich oils and recent clinical results.
Keywords: Omega-3s, Schizochytrium, Fish oil, EPA, DHA
Current Diabetes Reviews
Title: Omega-3 Fatty Acids for Nutrition and Medicine: Considering Microalgae Oil as a Vegetarian Source of EPA and DHA
Volume: 3 Issue: 3
Author(s): Scott D. Doughman, Srirama Krupanidhi and Carani B. Sanjeevi
Affiliation:
Keywords: Omega-3s, Schizochytrium, Fish oil, EPA, DHA
Abstract: Long-chain EPA/DHA omega-3 fatty acid supplementation can be co-preventative and co-therapeutic. Current research suggests increasing accumulated long chain omega-3s for health benefits and as natural medicine in several major diseases. But many believe plant omega-3 sources are nutritionally and therapeutically equivalent to the EPA/DHA omega-3 in fish oil. Although healthy, precursor ALA bio-conversion to EPA is inefficient and production of DHA is nearly absent, limiting the protective value of ALA supplementation from flax-oil, for example. Along with pollutants certain fish acquire high levels of EPA/DHA as predatory species. However, the origin of EPA/DHA in aquatic ecosystems is algae. Certain microalgae produce high levels of EPA or DHA. Now, organically produced DHA-rich microalgae oil is available. Clinical trials with DHA-rich oil indicate comparable efficacies to fish oil for protection from cardiovascular risk factors by lowering plasma triglycerides and oxidative stress. This review discusses 1) omega-3 fatty acids in nutrition and medicine; 2) omega-3s in physiology and gene regulation; 3) possible protective mechanisms of EPA/DHA in major diseases such as coronary heart disease, atherosclerosis, cancer and type 2 diabetes; 4) EPA and DHA requirements considering fish oil safety; and 5) microalgae EPA and DHA-rich oils and recent clinical results.
Export Options
About this article
Cite this article as:
Scott D. Doughman , Srirama Krupanidhi and Carani B. Sanjeevi , Omega-3 Fatty Acids for Nutrition and Medicine: Considering Microalgae Oil as a Vegetarian Source of EPA and DHA, Current Diabetes Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339907781368968
DOI https://dx.doi.org/10.2174/157339907781368968 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nebulizer Therapy in Pulmonology: Review of the Literature
Current Respiratory Medicine Reviews Development of Monoclonal Antibody Against Chlorinated 192tyrosine Containing ApoAI Peptide to Screen Quality of Human High Density Lipoprotein (HDL)
Protein & Peptide Letters Out-of-Hospital Cardiac Arrest –Optimal Management
Current Cardiology Reviews Fructose-1,6-bisphosphatase Inhibitors: A Review of Recent (2000- 2017) Advances and Structure-Activity Relationship Studies
Current Medicinal Chemistry Biomarkers as a Guide of Medical Treatment in Cardiovascular Diseases
Current Medicinal Chemistry Device-based Therapies for Resistant Hypertension
Current Pharmaceutical Design New Inotropic Pharmacologic Strategies Targeting the Failing Myocardiumin the Newborn and Infant
Mini-Reviews in Medicinal Chemistry Blood Pressure and White Matter Lesions in Patients with Vascular Disease: The SMART-MR Study
Current Neurovascular Research Oligonucleotide Aptamers for Glioma Targeting: An Update
Central Nervous System Agents in Medicinal Chemistry Difference in the Influence of the Lipid Profile as a Coronary Risk Factor in Patients with and Without Diabetes Mellitus
Vascular Disease Prevention (Discontinued) Disease Modifying Osteoarthritis Drugs: Facing Development Challenges and Choosing Molecular Targets
Current Drug Targets Ageing Mechanisms and Associated Lipid Changes
Current Vascular Pharmacology Evaluating Oxidative Stress in Human Cardiovascular Disease: Methodological Aspects and Considerations
Current Medicinal Chemistry Targeting Mitochondria for Cardiac Protection
Current Drug Targets Phytochemicals from Peanut (<i>Arachis hypogaea</i> L.) Skin Extract with Potential for Pharmacological Activity
Current Bioactive Compounds A Glance on the Role of Bacterial Siderophore from the Perspectives of Medical and Biotechnological Approaches
Current Drug Targets Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design Stem Cell Patents: An Innovative Approach to Anti-Cancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design